Who Paid My Doc
A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study
Research payments
$1,348,502
Through program year 2025, $1,348,502 in research payments was reported against A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study, across 248 payments, paid by Janssen Research & Development, LLC.
- Paid by
- Janssen Research & Development, LLC
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $113,262 | 35 |
| 2020 | Research | $500,471 | 125 |
| 2019 | Research | $734,769 | 88 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Ranjana Advani Palo Alto, CA Named on 31 payments
- Steven Coutre Palo Alto, CA Named on 31 payments
- Jay Yang Detroit, MI Named on 24 payments
- Ebenezer Kio Goshen, IN Named on 22 payments
- Dean Kirkel Marietta, GA Named on 16 payments
- Frederick Lansigan Lebanon, NH Named on 12 payments
- Marc Hoffmann Overland Park, KS Named on 12 payments
- Nancy Bartlett Saint Louis, MO Named on 10 payments
- Don Stevens Louisville, KY Named on 9 payments
- Jeff Sharman Eugene, OR Named on 9 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.